The main risk is execution under a
premium valuation. Ouster must turn
Rev8, BlueCity, and
Stereolabs into validated production revenue before supplier concentration, hardware pricing pressure, and possible
dilution blunt the margin story. The demand backdrop can be strong, but if value capture stays mostly in hardware and
qualification cycles drag, the business may scale while the stock underwhelms.